Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 for the Treatment of Moderate to Severe Glabellar Lines
NCT06308198Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 3
01
Overview
A Phase 3 trial of trenibotulinumtoxinE in glabellar lines, sponsored by AbbVie Inc.. Started Mar 2024; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06308198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308198.